Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
49 Results for "
Temozolomide
" in MedChemExpress (MCE) Product Catalog:
Products (49)
49 Results for "Temozolomide" in MCE Product Catalog:
Cat. No.: HY-17364R
CAS No.: 85622-93-1
Synonyms: NSC 362856 (Standard); CCRG 81045 (Standard); TMZ (Standard)
Research Areas:
Temozolomide (Standard) is the analytical standard of Temozolomide. This product is intended for research and analytical applications. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects .
Cat. No.: HY-15882
CAS No.: 1200127-66-7
Target:
Research Areas:
GNE-783 is a selective CHK1 inhibitor that enhances the activity of gemcitabine. GNE-783 improves the efficacy of anti-metabolite DNA damage drugs by inactivating S-phase and G2-phase cell cycle checkpoints following DNA damage. GNE-783 selectively enhances the chemical synergy of certain drugs in different tumor types, for example, enhancing the activity of temozolomide only in melanoma cell lines .
Cat. No.: HY-173116
CAS No.: 2051527-54-7
Target:
Research Areas:
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .
Cat. No.: HY-175299
Target:
Research Areas:
Hedgehog IN-11 is an orally active Hedgehog inhibitor. Hedgehog IN-11 downregulates the expression of O6-methylguanine-DNA methyltransferase (MGMT) to impair the Temozolomide (TMZ) (HY-17364) resistance by inhibiting the Hedgehog pathway. Hedgehog IN-11 shows improved inhibition of cell migration and invasion, and induced cell apoptosis in TMZ-resistant GBM cell lines. Hedgehog IN-11 is predicted by computer simulation to have good blood-brain barrier penetration. Hedgehog IN-11 can be used for the study of glioblastoma (GBM) .
Cat. No.: HY-155580
CAS No.: 2927489-99-2
Target:
Research Areas:
MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape [1].
Cat. No.: HY-169439
CAS No.: 449187-98-8
Research Areas:
Temozolomide-amino hydrochloride (compound 8) is an activity control for the target protein ligand of Naph-Se-TMZ (HY-169433) .
Cat. No.: HY-155889
Target:
Research Areas:
IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
Cat. No.: HY-B0106S1
CAS No.: 1217851-16-5
Synonyms: UCB L059-d3
Cat. No.: HY-12772R
CAS No.: 112559-91-8
Synonyms: Itraconazole metabolite Hydroxy Itraconazole (Standard); R-63373 (Standard)
Target:
Research Areas:
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
Cat. No.: HY-119696R
CAS No.: 3413-72-7
Target:
Research Areas:
MTIC (Standard) is the analytical standard of MTIC. This product is intended for research and analytical applications. MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity
[1][2][3][4].
Cat. No.: HY-14688
CAS No.: 374071-46-2
CEP-8983 is a PARP-1 and PARP-2 inhibitor (IC50: 20 and 6 nM). CEP-8983 is an effective chemosensitizing agent, and can sensitize chemotherapy-resistant cell lines and subcutaneous xenografts to Temozolomide (HY-17364) and Camptothecin (HY-16560) .
Cat. No.: HY-157168
Target:
Research Areas:
TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC50 of 68.99 μM .
Cat. No.: HY-119696S
CAS No.: 1185242-69-6
Cat. No.: HY-14206
CAS No.: 188106-83-4
NU 1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor with a Ki of 6 nM. NU 1085 shows strong cytotoxicity to cancer cells (LC50 = 83-94 μM) and can enhance the anticancer effect of Temozolomide (HY-17364). NU 1085 can be used for the research of cancer, such as lung cancer .
Cat. No.: HY-149003
CAS No.: 2494001-21-5
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent PARP1 inhibitor with an IC50 value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .
Cat. No.: HY-169433
Target:
Research Areas:
Naph-Se-TMZ is a PROTAC-like HDAC1 degrader. Naph-Se-TMZ induces ROS-dependent reduction in HDAC1 protein expression and total HDAC activity, and decreases cell viability in a dose-dependent manner. Naph-Se-TMZ exhibits activity in both TMZ-sensitive and TMZ-resistant glioma cells, and its cytotoxicity is reversed by the ROS scavenger N-acetylcysteine (HY-B0215). Naph-Se-TMZ can be used in studies related to glioblastoma .
Naph-Se-TMZ consists of a target protein ligand (red segment): Temozolomide (HY-17364), a DNA intercalator (blue segment): Nitro-Naphthalimide-C2-acylamide (HY-169437), and a molecular linker (black segment). Meanwhile, the activity control for the target protein ligand is Temozolomide-amino hydrochloride (HY-169439), and the DNA intercalator+linker is NNISC-2 (HY-169438).
Naph-Se-TMZ consists of a target protein ligand (red segment): Temozolomide (HY-17364), a DNA intercalator (blue segment): Nitro-Naphthalimide-C2-acylamide (HY-169437), and a molecular linker (black segment). Meanwhile, the activity control for the target protein ligand is Temozolomide-amino hydrochloride (HY-169439), and the DNA intercalator+linker is NNISC-2 (HY-169438).
Cat. No.: HY-119992
CAS No.: 609848-02-4
CEP-6800 is an inhibitor of PARP-1 with chemopotentiating ability. CEP-6800 attenuates irinotecan (HY-16562)- and Temozolomide (HY-17364)-induced poly(ADP-ribose) accumulation in LoVo as well as HT29 xenografts. CEP-6800 can suppress Calu-6 tumor growth. CEP-6800 can be studied in anti-cancer research .
Cat. No.: HY-10261BR
CAS No.: 439081-18-2
Synonyms: (E/Z)-BIBW 2992 (Standard)
Research Areas:
(E/Z)-Afatinib (Standard) is the analytical standard of (E/Z)-Afatinib. This product is intended for research and analytical applications. (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
Cat. No.: HY-169002
Target:
Research Areas:
PP5-IN-2 is an orally active and selective protein phosphatase 5 (PP5) inhibitor with an IC50 value of 0.9 μM. PP5-IN-2 activates p53 and downregulates cyclin D1 and MGMT, which shows potency in cell cycle arrest and reverses Temozolomide (TMZ) (HY-17364) resistance in the U87 MG cell line. PP5-IN-2 effectively inhibits tumor growth in the xenograft mouse model .
Cat. No.: HY-159580
STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1 .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
